The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cetuximab and vemurafenib plus liposomal irinotecan (II), leucovorin and fluorouracil for BRAFV600E-mutated advanced colorectal cancer (IMPROVEMENT2): A multicenter, open-label, randomized controlled trial.
 
Zhan Wang
No Relationships to Disclose
 
Chen-Yang Ye
No Relationships to Disclose
 
Xiao-Dong Jiao
No Relationships to Disclose
 
Ke Liu
No Relationships to Disclose
 
Bao-Dong Qin
No Relationships to Disclose
 
Wen-Xin Zhai
No Relationships to Disclose
 
Biao-Long Yang
No Relationships to Disclose
 
Li Sun
No Relationships to Disclose
 
Wei-Ping Dai
No Relationships to Disclose
 
Yan Ling
No Relationships to Disclose
 
Ying Wu
No Relationships to Disclose
 
Shi-Qi Chen
No Relationships to Disclose
 
Ying-Fu Zhang
No Relationships to Disclose
 
Dong-Min Shi
No Relationships to Disclose
 
Xiao-Peng Duan
No Relationships to Disclose
 
Xue Zhong
No Relationships to Disclose
 
Xi He
No Relationships to Disclose
 
Cheng-Hao Jia
No Relationships to Disclose
 
Yuan-Sheng Zang
No Relationships to Disclose